Related Experiment Video
Updated: Aug 20, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Antitumor Activities of Interleukin-12 in Melanoma
Wei Gao1, Jun Pan2, Jianping Pan1
1Institute of Translational Medicine, Zhejiang University City College, Hangzhou 310015, China.
Abstract:
Melanoma is the most common and serious malignant tumor among skin cancers. Although more and more studies have revolutionized the systematic treatment of advanced melanoma in recent years, access to innovative drugs for melanoma is still greatly restricted in many countries. IL-12 produced mainly by antigen-presenting cells regulates the immune response and affects the differentiation of T cells in the process of antigen presentation. However, the dose-limited toxicity of IL-12 limits its clinical application. The present review summarizes the basic biological functions and toxicity of IL-12 in the treatment of melanoma and discusses the clinical application of IL-12, especially the combination of IL-12 with immune checkpoint inhibitors, cytokines and other therapeutic drugs. We also summarize several promising technological approaches such as carriers that have been developed to improve the pharmacokinetics, efficacy and safety of IL-12 or IL-12 encoding plasmid application.
Insights
Interleukin-12 (IL-12) shows promise for melanoma treatment but faces toxicity challenges. Novel drug delivery systems and combinations with other therapies aim to improve its efficacy and safety for advanced skin cancer.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma remains a significant malignant skin cancer with restricted access to advanced treatments globally.
- Interleukin-12 (IL-12), crucial for immune responses in antigen presentation, has dose-limited toxicity hindering clinical use.
- IL-12 regulates T cell differentiation and immune responses, making it a potential therapeutic agent for melanoma.
Purpose of the Study:
- To review the biological functions and toxicity of IL-12 in melanoma treatment.
- To discuss current and potential clinical applications of IL-12, including combination therapies.
- To explore advanced delivery systems for enhancing IL-12 or IL-12 encoding plasmid efficacy and safety.
Main Methods:
- Literature review of basic biological functions, toxicity, and clinical applications of IL-12 in melanoma.
- Analysis of combination strategies involving IL-12 with immune checkpoint inhibitors, cytokines, and other drugs.
- Summary of technological approaches, such as carrier systems, for improving IL-12 pharmacokinetics and safety.
Main Results:
- IL-12 plays a key role in immune regulation relevant to melanoma, but its clinical utility is constrained by toxicity.
- Combination therapies and novel delivery systems show potential to overcome IL-12 limitations.
- Improved pharmacokinetic profiles and targeted delivery can enhance the therapeutic index of IL-12 for melanoma.
Conclusions:
- IL-12 holds therapeutic potential for melanoma, necessitating strategies to mitigate toxicity and improve delivery.
- Combining IL-12 with other agents and utilizing advanced carriers are promising avenues for effective melanoma treatment.
- Further research into optimized IL-12 application is crucial for advancing melanoma care.
Related Concept Videos
01:27Tumor Immunotherapy
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...